

HIV Vaccine Clinical Trials Pipeline

Approach	Description	Key Candidates	Trials	Funders/Developers
Neutralizing Antibody Induction	Designed to induce generalized neutralizing antibody responses, as opposed to targeting a specific bNAb response	<ul style="list-style-type: none"> • BG505 trimers on mRNA platform • UVAX-1107, UVAX-1197 	HVTN 302, HVTN 313 HVTN 319, UVAX-HIV-101	HVTN, UVAX Bio LLC
Non-Neutralizing Antibody Induction	Designed to induce a generalized cellular (T-cell) immune response against HIV infection	<ul style="list-style-type: none"> • ALFQ vector-based vaccines • Ad4 vector-based intranasal vaccines • Chimp-Ad gp140 + gp120 vaccine 	HVTN 139, HVTN 318, RV 546, RV 575, RV 591	HVTN, MHRP
CD8+ T-Cell Induction	Designed to induce T-cell responses to inhibit HIV replication and kill HIV-infected cells	<ul style="list-style-type: none"> • GrAdHIVNE1, VIR-1388 HCMV 	IAVI C114, VIR-1388-V101	HVTN, IAVI, Gates Foundation, Vir Biotechnology
Germline Targeting	CD4 Binding Site	Designed to initiate a bNAb response targeted to a specific site on the HIV envelope (e.g., CD4 binding site, V3 glycan, multiple)	<ul style="list-style-type: none"> • eOD-GT8 60mer • BG505 SOSIP gp140; BG505 GT1.1 • 426.Mod.Core-C4B • CH505 TF chTrimer 	BRILLIANT-011, HVTN 300, HVTN 301 HVTN 312, HVTN 316 HVTN 320, IAVI G002 IAVI C107, IAVI C110
	V3 Glycan	through an antibody pathway encoded by a particular germline antibody.	<ul style="list-style-type: none"> • N332-GT5 gp140 	HVTN 144, HVTN 307 HVTN 321
	CD4 Binding Site & V3 Glycan	Accomplished through a series of immunizations	<ul style="list-style-type: none"> • eOD-GT8 60mer mRNA + coreg28v2 60mer mRNA • N332 GT5 mRNA 	G004



January 2026